Straits Times Index
3,294.25 +1.56 (+0.05%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,164.55 +401.52 (+2.26%) FTSE 100
8,121.24 -22.89 (-0.28%) Bitcoin USD
57,454.59 -2,361.26 (-3.95%) CMC Crypto 200
1,261.25 -9.50 (-0.75%)
scPharmaceuticals Inc. (SCPH)
After hours:
- GlobeNewswire
scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection
FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and
- Simply Wall St.
Those who invested in scPharmaceuticals (NASDAQ:SCPH) five years ago are up 62%
scPharmaceuticals Inc. ( NASDAQ:SCPH ) shareholders might be concerned after seeing the share price drop 23% in the...
- Insider Monkey
scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2023 Earnings Call Transcript
scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2023 Earnings Call Transcript March 13, 2024 scPharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.35, expectations were $-0.48. SCPH isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to scPharmaceuticals Fourth Quarter and […]
